Microbial Natural Products and Biopharmaceuticals: From Antibiotic Discovery to Modern Therapeutic Applications

Abstract

Microorganisms have long been known to be a source of biologically active molecules with great medical and pharmaceutical applications. The identification of penicillin opened the door to the development of drugs and stimulated a range of investigations into the microbial metabolites that could be used to treat disease. Since then, bacteria and fungi have been used to produce a variety of compounds with antibacterial, antifungal, anticancer, immunosuppressive, anti-inflammatory, and antibiofilm properties. The review highlights the significance of microbial natural products in drug discovery, particularly in the development of key therapeutic molecules from bacteria and fungi. Modern medicine was transformed by classical antibiotics, such as penicillin, streptomycin, tetracycline, erythromycin, and vancomycin, which greatly enhanced health worldwide by curing infectious diseases. Other compounds found in microbial metabolites have also been used in cancer therapy, including bleomycin, daunorubicin, doxorubicin, rapamycin, and geldanamycin that affect pathways that control cellular proliferation and tumor development. More recently, microbial compounds with antibiofilm, anti-inflammatory, antiparasitic, and metabolic regulatory activities have shown further therapeutic potential. The increasing global problem of antimicrobial resistance, however, has stimulated the search for new bioactive molecules that are produced by microorganisms that have not yet been characterized. The next generation of therapeutics discovery and optimization is being driven by emerging technologies such as genomics, synthetic biology, metabolic engineering, and production platforms based on biotechnology. In sum, microbial natural products are crucial to the development of pharmaceuticals and to solving today and tomorrow's global health needs.